Related references
Note: Only part of the references are listed.Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD
M. Gutfleisch et al.
EYE (2011)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Arterial Thromboembolic Events in Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab
Angela M. Carneiro et al.
OPHTHALMOLOGICA (2011)
Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study
Frank G. Holz et al.
OPHTHALMOLOGY (2011)
Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2011)
Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration
Lesley H. Curtis et al.
ARCHIVES OF OPHTHALMOLOGY (2010)
Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation
Tarek S. Hemeida et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2010)
Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab
K. Matsuyama et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2010)
Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone for Therapy-Resistant Exudative Age-Related Macular Degeneration
Yong Tao et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2010)
A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
Geeta A. Lalwani et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2009)
VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration
James A. Dixon et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
David M. Brown et al.
OPHTHALMOLOGY (2009)
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1
Carl D. Regillo et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial
L. J. Singerman et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2008)
The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration
Salvatore Grisanti et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2008)
Pharmacokinetics of intravitreal ranibizumab (Lucentis)
Sophie J. Bakri et al.
OPHTHALMOLOGY (2007)
Penetration of bevacizumab through the retina after intravitreal injection in the monkey
Peter Heiduschka et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2007)
Pharmacokinetics of intravitreal bevackumab (avastin)
Sophie J. Bakri et al.
OPHTHALMOLOGY (2007)
Triple therapy for choroidal neovascularization due to agerelated macular degeneration - Verteporfin PDT, bevacimmab, and dexamethasone
Albert J. Augustin et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2007)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration - Twelve-week results of an uncontrolled open-label clinical study
S Michels et al.
OPHTHALMOLOGY (2005)
Current concepts in the pathogenesis of age-related macular degeneration
MA Zarbin
ARCHIVES OF OPHTHALMOLOGY (2004)
The epidemiology of age-related macular degeneration
R Klein et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2004)
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
MS Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys
DW Drolet et al.
PHARMACEUTICAL RESEARCH (2000)
Share Paper
